Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

Maintenance treatment with vedolizumab (Entyvio) appeared to be safe and effective in children with inflammatory bowel disease (IBD), with greater effectiveness in those with ulcerative colitis ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Doctors may prescribe this treatment for people with severe IBD that has not responded to ... and vedolizumab (Entyvio). This therapy prevents lymphocytes (a type of white blood cells that cause ...

Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

of golimumab were able to see improvements in ulcerative colitis by week 30 of treatment. This was compared to 15.6% of ...

known as Entyvio SC, Spherix captured the initial impact of the launch on the EU5 Crohn’s disease (CD) and ulcerative colitis (UC) markets through their RealTime DynamixTM services. The latest ...

Treatment with Entyvio is the same for ulcerative colitis, Crohn’s disease and pouchitis. The recommended dose of Entyvio is 300 mg per infusion. Following the initial dose, you will get ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...